RO7248824
Sponsors
Hoffmann-La Roche
Conditions
Angelman Syndrome
Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)
CompletedNCT04428281
Start: 2020-08-19End: 2025-07-31Updated: 2025-08-24
A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants
CompletedNCT04863794
Start: 2021-04-29End: 2022-08-01Updated: 2022-09-08